A $2.9 million funding injection from the Federal Government will support the rollout of a new saliva-based genetic test for glaucoma in Australia. The Adelaide team behind the technology believe it holds
Read More
Positive results for PolyActiva biodegradable implant for glaucoma
Melbourne-based ophthalmology company, PolyActiva, has reported promising clinical trial results for its six-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.
Read More
Read More
iTrack six-year data reveals long-term efficacy and safety profile
Adelaide-based Nova Eye Medical has announced the publication of six-year data of its iTrack canaloplasty microcatheter. Published in the Journal of Glaucoma, the data demonstrates its long-term efficacy and safety profile.
Read More
Read More
Tapping into ophthalmic opportunities
AFT Pharmaceuticals is highly selective about the products it brings to the Australasian market – and its eyecare portfolio exemplifies this. CEO Dr Hartley Atkinson discusses the company’s dual role as a distributor and innovator on the local ophthalmic scene.
Read More
Read More
Project investigating IOP in youngsters receives 2023 Quinlivan Research Grant
Western Australian ophthalmologist Professor David Mackey has been awarded the 2023 Glaucoma Australia (GA) ‘Quinlivan’ Research Grant. He will use the funds to investigate the normal range of intraocular pressure (IOP) in children and young adults, and whether it predicts glaucoma later in life.
Read More
Read More
SiGHTWiSE: Glaucoma Australia gives patient support program a new name
Glaucoma Australia has announced the new name of its patient support program. SiGHTWiSE, the new brand identity, signals a brighter future for people diagnosed with glaucoma and their families, the organisation says.
Read More
Read More
Eye and Ear seeks more optometrists for expanding glaucoma collaborative care program
The Royal Victorian Eye and Ear Hospital (Eye and Ear) is inviting Victorian optometrists to participate in an innovative care program for patients with mild to moderate glaucoma.
Read More
Read More
Visual field virtual headset offers new reality
Significant growth in patient numbers at DR DAVID O’NEILL’s independently-owned optometry practice on the Sunshine Coast has created a bottleneck when conducting visual field testing, leading him to find a speedier solution.
Read More
Read More
Flinders University to trial SLT for high risk glaucoma patients in world first
In a world first, ophthalmology experts at Flinders University will trial early intervention treatment, selective laser trabeculoplasty (SLT), to prevent people at high risk of glaucoma from developing loss of sight from the disease.
Read More
Read More
Alcon Hydrus – a MIGS microstent with macro results
The Hydrus Microstent, now owned by Alcon, has helped change the game when it comes to surgical options in glaucoma. Associate Professor ASHISH AGAR reflects on the MIGS device’s past, present and future in Australia.
Read More
Read More